Protein Supplementation in Infants With Brain Injury
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Head circumference
研究概览
简要总结
To date, few studies have been done regarding nutrition supplementation in infants with brain injury. Therefore, the investigators are proposing to study the effects of protein supplementation in this group of babies. The investigators will recruit 24 infants with brain injury (evidence of hemorrhage, white matter injury, or gray matter injury) admitted to the Cincinnati Children's Hospital Neonatal Intensive Care Unit (NICU) into the study. Upon diagnosis, the investigators will obtain consent from the parents for participation in the study, then randomly assign the baby to one of two groups - an increased protein group and a control group. Both groups of infants will be monitored to ensure no adverse effects occur due to the supplementation.
Protein supplementation will continue for the first 12 months of age. Growth parameters, such as weight, length, and head circumference, will be measured while the infant is the NICU. Head circumference will be measured in the investigators outpatient clinic at three, six, and 12 months of age. At 18-22 months, the infants will be tested for neurodevelopmental outcomes using the Bayley Scales of Infant Development. The investigators hypothesize that infants who receive the additional protein will demonstrate increased head growth and improved neurodevelopmental outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 2 Days 至 3 Weeks(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Infants admitted to the NICU at CCHMC
- •Known or suspected brain injury
- •Parental consent obtained
- •At least 48 hours of age at the time of randomization
排除标准
- •Congenital or posthemorrhagic hydrocephalus
- •Major congenital brain malformations
- •Congenital gastrointestinal malformations or Bell Stage III NEC
- •Inborn errors of metabolism
- •Chromosomal abnormalities
- •Significant cardiac disease
结局指标
主要结局
Head circumference
时间窗: 12 months of age +/- 4 weeks
次要结局
- Neurodevelopmental outcome on Bayley Scales of Infant Development(18-22 months)
- Weight and length(3, 6, 12 months of age)
